SCHEMBL7864367

SCHEMBL7864367

COC(=O)c1cccc(N=C=S)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.42
FFAR4 Q5NUL3 1/20 0.42
ALDH1A1 P00352 5/20 0.41
HSD17B10 Q99714 2/20 0.41
CFTR P13569 1/20 0.41
MAPT P10636 4/20 0.41
THRB P10828 1/20 0.41
CYP3A4 P08684 1/20 0.41
KDM4E B2RXH2 4/20 0.40
HPGD P15428 1/20 0.40
POLB P06746 2/20 0.40
ATM Q13315 1/20 0.40
MYC P01106 1/20 0.40
APLNR P35414 1/20 0.40
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
MAPK10 P53779 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3125776 0.86 CYP3A4 (0.59) LMNATSHRFFAR4ALDH1A1HSD17B10
SCHEMBL31200496 0.85 ALDH1A1 (0.50) LMNATSHRALDH1A1HSD17B10CFTR
SCHEMBL910030 0.85 ALDH1A1 (0.50) LMNATSHRALDH1A1HSD17B10CFTR
SCHEMBL10083848 0.80 LMNA (0.47) LMNATSHRFFAR4ALDH1A1HSD17B10
SCHEMBL2349959 0.77 APLNR (0.38) LMNATSHRALDH1A1HSD17B10CFTR
SCHEMBL3511612 0.77 LMNA (0.59) LMNATSHRFFAR4ALDH1A1HSD17B10
SCHEMBL543373 0.76 ALDH1A1 (0.44) LMNATSHRFFAR4ALDH1A1HSD17B10
SCHEMBL1995839 0.75 CYP3A4 (0.60) LMNATSHRALDH1A1HSD17B10CYP3A4
SCHEMBL18367781 0.75 LMNA (0.42) LMNATSHRFFAR4ALDH1A1HSD17B10
SCHEMBL18029472 0.74 MAPT (0.36) LMNATSHRALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 US disclosed
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 US disclosed
WO-2008005368-A2 PIPERAZINES AS P2X7 ANTAGONISTS ABBOTT LABORATORIES (US) 2008-01-10 WO disclosed
EP-1144396-A2 SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS Bayer Corporation (US) 2001-10-17 EP disclosed
WO-2000042031-A2 SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS BAYER CORPORATION (US) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076924-A1 Piperazines as P2X7 antagonists P2RX7, P2RX1, P2RX2 LMNA 2852/4885TSHR 2283/4885FFAR4 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.